全球抗感染劑市場規模、佔有率、趨勢和成長分析報告（2026-2034年）

預計抗感染劑市場將從 2025 年的 1,572.5 億美元成長到 2034 年的 1,866.1 億美元，2026 年至 2034 年的複合年成長率為 1.92%。

隨著感染疾病持續構成全球重大健康挑戰，全球抗感染劑市場正不斷擴大。抗感染劑，包括抗生素、抗病毒藥物、抗真菌藥物和抗寄生蟲藥物，在治療多種感染疾病發揮至關重要的作用。感染疾病上升、全球旅行增加以及對新興病原體的日益關注，是推動對有效抗感染療法需求的主要因素。

市場成長也得益於醫藥研發的持續進步和創新藥物製劑的開發。各國政府和醫療機構正加大對疾病監測系統和感染控制計畫的投入，進一步推動了抗感染治療需求的成長。此外，發展中地區醫療基礎設施的擴建和藥品可近性的提高，也使得這些必要的治療能夠惠及更多患者。

全球抗感染劑市場前景依然光明，主要得益於持續進行的下一代抗菌藥物和聯合治療研發工作。生物技術創新和先進的藥物發現平台有望加速新型抗感染藥物的上市。此外，全球衛生安全和疫情應對日益受到重視，也可能刺激對感染疾病治療方案的投資。隨著醫療系統將有效控制感染作為優先事項，預計該市場將繼續擴張。

目錄

第1章：引言

第2章執行摘要

第3章 市場變數、趨勢與框架

• 市場譜系展望
• 滲透率和成長前景分析
• 價值鏈分析
• 法律規範
  • 標準與合規性
  • 監管影響分析
• 市場動態
  • 市場促進因素
  • 市場限制因素
  • 市場機遇
  • 市場挑戰
• 波特五力分析
• PESTLE分析

第4章：全球抗感染劑市場：按類型分類

• 市場分析、洞察與預測
• 抗菌藥物（頭孢菌素類、青黴素類、Fluoroquinolones、大環內酯類、碳青黴烯類等）
• 抗病毒藥物
• 抗黴菌藥物（Azole、Echinocandins、Polyenes等）

第5章：全球抗感染劑市場：依給藥途徑分類

• 市場分析、洞察與預測
• 口服
• 腸外
• 局部的
• 其他

第6章 全球抗感染劑市場：依通路分類

• 市場分析、洞察與預測
• 醫院藥房
• 零售藥房
• 其他

第7章 全球抗感染劑市場：依地區分類

• 區域分析
• 北美市場分析、洞察與預測
  • 美國
  • 加拿大
  • 墨西哥
• 歐洲市場分析、洞察與預測
  • 英國
  • 法國
  • 德國
  • 義大利
  • 俄羅斯
  • 其他歐洲國家
• 亞太市場分析、洞察與預測
  • 印度
  • 日本
  • 韓國
  • 澳洲
  • 東南亞
  • 其他亞太國家
• 拉丁美洲市場分析、洞察與預測
  • 巴西
  • 阿根廷
  • 秘魯
  • 智利
  • 其他拉丁美洲國家
• 中東和非洲市場分析、洞察與預測
  • 沙烏地阿拉伯
  • UAE
  • 以色列
  • 南非
  • 其他中東和非洲國家

第8章 競爭情勢

• 最新趨勢
• 公司分類
• 供應鏈和銷售管道合作夥伴（根據現有資訊）
• 市場佔有率和市場定位分析（基於現有資訊）
• 供應商情況（基於現有資訊）
• 策略規劃

第9章：公司簡介

• 主要公司的市佔率分析
• 公司簡介
  • Pfizer Inc
  • Merck & Co. Inc
  • Gilead Sciences Inc
  • AbbVie
  • Bristol-Myers Squibb
  • AstraZeneca
  • Sandoz International GmbH
  • Bayer AG
  • Xellia Pharmaceuticals
  • Mankind Pharma
  • B. Braun SE
  • Boehringer Ingelheim

The Anti-Infective Agents Market size is expected to reach USD 186.61 Billion in 2034 from USD 157.25 Billion (2025) growing at a CAGR of 1.92% during 2026-2034.

The Global Anti-Infective Agents Market is expanding as infectious diseases continue to pose significant health challenges across the globe. Anti-infective agents, including antibiotics, antivirals, antifungals, and antiparasitic drugs, play a crucial role in treating a wide range of infections. Increasing incidences of infectious diseases, growing global travel, and rising concerns about emerging pathogens are major factors driving the demand for effective anti-infective therapies.

Market growth is also supported by continuous advancements in pharmaceutical research and the development of innovative drug formulations. Governments and healthcare organizations are investing in improved disease surveillance systems and infection control programs, which are contributing to increased demand for anti-infective treatments. Furthermore, the expansion of healthcare infrastructure and improved access to medicines in developing regions are enabling broader patient access to these essential therapies.

The future of the Global Anti-Infective Agents Market remains promising as ongoing research focuses on developing next-generation antimicrobial therapies and combination treatments. Biotechnology innovations and advanced drug discovery platforms are expected to accelerate the introduction of new anti-infective drugs. In addition, the growing emphasis on global health security and pandemic preparedness will likely drive investments in infectious disease treatment solutions. As healthcare systems prioritize effective infection management, the market is expected to continue expanding.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Type

• Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others)
• Antivirals
• Antifungals (Azoles, Echinocandins, Polyenes, Others)

By Route of Administration

• Oral
• Parenteral
• Topical
• Others

By Distribution Channel

• Hospital Pharmacies
• Retail Pharmacies
• Others

COMPANIES PROFILED

• Pfizer Inc, Merck Co Inc, Gilead Sciences Inc, AbbVie, BristolMyers Squibb, AstraZeneca, Sandoz International GmbH, Bayer AG, Xellia Pharmaceuticals, Mankind Pharma, B Braun SE, Boehringer Ingelheim
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Type
• 4.2. Antibacterials (Cephalosporins, Penicillin, Fluoroquinolones, Macrolides, Carbapenem, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Antivirals Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Antifungals (Azoles, Echinocandins, Polyenes, Others) Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Route Of Administration
• 5.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Parenteral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Distribution Channel
• 6.2. Hospital Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Retail Pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Others Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL ANTI-INFECTIVE AGENTS MARKET: BY REGION 2022-2034(USD MN)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.2.1 By Type
  • 7.2.2 By Route Of Administration
  • 7.2.3 By Distribution Channel
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.3.1 By Type
  • 7.3.2 By Route Of Administration
  • 7.3.3 By Distribution Channel
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.4.1 By Type
  • 7.4.2 By Route Of Administration
  • 7.4.3 By Distribution Channel
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.5.1 By Type
  • 7.5.2 By Route Of Administration
  • 7.5.3 By Distribution Channel
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 7.6.1 By Type
  • 7.6.2 By Route Of Administration
  • 7.6.3 By Distribution Channel
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL ANTI-INFECTIVE AGENTS INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 Pfizer Inc
  • 9.2.2 Merck & Co. Inc
  • 9.2.3 Gilead Sciences Inc
  • 9.2.4 AbbVie
  • 9.2.5 Bristol-Myers Squibb
  • 9.2.6 AstraZeneca
  • 9.2.7 Sandoz International GmbH
  • 9.2.8 Bayer AG
  • 9.2.9 Xellia Pharmaceuticals
  • 9.2.10 Mankind Pharma
  • 9.2.11 B. Braun SE
  • 9.2.12 Boehringer Ingelheim